Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTYQA8A6)

• DOT Name: Ferritin light chain (FTL)
• Synonyms: Ferritin L subunit
• Gene Name: FTL
• Related Disease:
  Hereditary hyperferritinemia with congenital cataracts
  Acute myelogenous leukaemia
  Benign prostatic hyperplasia
  Bone osteosarcoma
  Cataract
  Choreatic disease
  Colorectal carcinoma
  Depression
  Dystonia
  Gestational trophoblastic neoplasia
  Hemochromatosis
  Hepatitis B virus infection
  Hepatocellular carcinoma
  Hydatidiform mole
  Hypopigmentation of the skin
  Inflammatory bowel disease
  Iron metabolism disease
  Keloid
  L-ferritin deficiency
  Melanoma
  Mood disorder
  Movement disorder
  Neurodegeneration with brain iron accumulation
  Neuroferritinopathy
  Obesity
  Osteosarcoma
  Prostate cancer
  Prostate carcinoma
  Psychotic disorder
  Rheumatoid arthritis
  Trichohepatoenteric syndrome
  Adult glioblastoma
  Glioblastoma multiforme
  Head-neck squamous cell carcinoma
  Parkinsonian disorder
  Obsolete genetic hyperferritinemia without iron overload
  Amyotrophic lateral sclerosis
  Breast cancer
  Breast carcinoma
  Gastritis
  Hereditary hemochromatosis
  Osteoarthritis
  Venous thromboembolism
• UniProt ID: FRIL_HUMAN
• PDB ID: 2FFX; 2FG4; 2FG8; 3KXU; 4V6B; 5LG8; 6TR9; 6TS0; 6TS1; 6TSA; 6TSF; 6TSJ; 6WX6
• Pfam ID: PF00210
• Sequence:
  MSSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKR
  EGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSA
  RTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD
• Function: Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney.
• KEGG Pathway:
  Porphyrin metabolism (hsa00860)
  Ferroptosis (hsa04216)
  Necroptosis (hsa04217)
  Mineral absorption (hsa04978)
• Reactome Pathway:
  Golgi Associated Vesicle Biogenesis (R-HSA-432722)
  Neutrophil degranulation (R-HSA-6798695)
  Iron uptake and transport (R-HSA-917937)
  Scavenging by Class A Receptors (R-HSA-3000480)

Molecular Interaction Atlas (MIA) of This DOT

43 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Hereditary hyperferritinemia with congenital cataracts	DISGL689	Definitive	Autosomal dominant	[1]
Acute myelogenous leukaemia	DISCSPTN	Strong	Altered Expression	[2]
Benign prostatic hyperplasia	DISI3CW2	Strong	Altered Expression	[3]
Bone osteosarcoma	DIST1004	Strong	Biomarker	[4]
Cataract	DISUD7SL	Strong	Genetic Variation	[5]
Choreatic disease	DISH8K3M	Strong	Genetic Variation	[6]
Colorectal carcinoma	DIS5PYL0	Strong	Altered Expression	[7]
Depression	DIS3XJ69	Strong	Biomarker	[8]
Dystonia	DISJLFGW	Strong	Genetic Variation	[9]
Gestational trophoblastic neoplasia	DIS4EJNA	Strong	Biomarker	[10]
Hemochromatosis	DISAPY0H	Strong	Genetic Variation	[11]
Hepatitis B virus infection	DISLQ2XY	Strong	Biomarker	[12]
Hepatocellular carcinoma	DIS0J828	Strong	Biomarker	[13]
Hydatidiform mole	DISKNP7O	Strong	Altered Expression	[10]
Hypopigmentation of the skin	DIS39YKC	Strong	Altered Expression	[14]
Inflammatory bowel disease	DISGN23E	Strong	Altered Expression	[15]
Iron metabolism disease	DISWDM9J	Strong	Biomarker	[16]
Keloid	DISV09JY	Strong	Biomarker	[17]
L-ferritin deficiency	DISVZ41G	Strong	Autosomal dominant	[18]
Melanoma	DIS1RRCY	Strong	Biomarker	[14]
Mood disorder	DISLVMWO	Strong	Altered Expression	[19]
Movement disorder	DISOJJ2D	Strong	Biomarker	[20]
Neurodegeneration with brain iron accumulation	DISRK4DZ	Strong	Biomarker	[21]
Neuroferritinopathy	DIS0E4F3	Strong	Autosomal dominant	[18]
Obesity	DIS47Y1K	Strong	Biomarker	[22]
Osteosarcoma	DISLQ7E2	Strong	Biomarker	[4]
Prostate cancer	DISF190Y	Strong	Biomarker	[23]
Prostate carcinoma	DISMJPLE	Strong	Biomarker	[23]
Psychotic disorder	DIS4UQOT	Strong	Biomarker	[24]
Rheumatoid arthritis	DISTSB4J	Strong	Altered Expression	[15]
Trichohepatoenteric syndrome	DISL3ODF	Strong	Genetic Variation	[25]
Adult glioblastoma	DISVP4LU	moderate	Biomarker	[26]
Glioblastoma multiforme	DISK8246	moderate	Biomarker	[26]
Head-neck squamous cell carcinoma	DISF7P24	moderate	Altered Expression	[27]
Parkinsonian disorder	DISHGY45	moderate	Genetic Variation	[24]
Obsolete genetic hyperferritinemia without iron overload	DIS165JG	Supportive	Autosomal dominant	[1]
Amyotrophic lateral sclerosis	DISF7HVM	Limited	Altered Expression	[28]
Breast cancer	DIS7DPX1	Limited	Biomarker	[29]
Breast carcinoma	DIS2UE88	Limited	Biomarker	[29]
Gastritis	DIS8G07K	Limited	Biomarker	[30]
Hereditary hemochromatosis	DISVG5MT	Limited	Biomarker	[31]
Osteoarthritis	DIS05URM	Limited	Biomarker	[32]
Venous thromboembolism	DISUR7CR	Limited	Biomarker	[33]

This DOT Affected the Drug Response of 1 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Paclitaxel	DMLB81S	Approved	Ferritin light chain (FTL) decreases the response to substance of Paclitaxel.	[67]

46 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the expression of Ferritin light chain (FTL).	[34]
Tretinoin	DM49DUI	Approved	Tretinoin increases the expression of Ferritin light chain (FTL).	[35]
Doxorubicin	DMVP5YE	Approved	Doxorubicin increases the expression of Ferritin light chain (FTL).	[36]
Cisplatin	DMRHGI9	Approved	Cisplatin increases the expression of Ferritin light chain (FTL).	[37]
Estradiol	DMUNTE3	Approved	Estradiol affects the expression of Ferritin light chain (FTL).	[38]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Ferritin light chain (FTL).	[39]
Temozolomide	DMKECZD	Approved	Temozolomide decreases the expression of Ferritin light chain (FTL).	[41]
Arsenic trioxide	DM61TA4	Approved	Arsenic trioxide increases the expression of Ferritin light chain (FTL).	[42]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide increases the expression of Ferritin light chain (FTL).	[43]
Triclosan	DMZUR4N	Approved	Triclosan increases the expression of Ferritin light chain (FTL).	[44]
Selenium	DM25CGV	Approved	Selenium increases the expression of Ferritin light chain (FTL).	[45]
Menadione	DMSJDTY	Approved	Menadione increases the expression of Ferritin light chain (FTL).	[43]
Folic acid	DMEMBJC	Approved	Folic acid affects the expression of Ferritin light chain (FTL).	[46]
Cannabidiol	DM0659E	Approved	Cannabidiol increases the expression of Ferritin light chain (FTL).	[47]
Rosiglitazone	DMILWZR	Approved	Rosiglitazone affects the expression of Ferritin light chain (FTL).	[48]
Ethanol	DMDRQZU	Approved	Ethanol increases the expression of Ferritin light chain (FTL).	[49]
Etoposide	DMNH3PG	Approved	Etoposide increases the expression of Ferritin light chain (FTL).	[37]
Sodium lauryl sulfate	DMLJ634	Approved	Sodium lauryl sulfate increases the expression of Ferritin light chain (FTL).	[50]
DTI-015	DMXZRW0	Approved	DTI-015 decreases the expression of Ferritin light chain (FTL).	[51]
Benzoic acid	DMKB9FI	Approved	Benzoic acid increases the expression of Ferritin light chain (FTL).	[50]
Gallium nitrate	DMF9O6B	Approved	Gallium nitrate increases the expression of Ferritin light chain (FTL).	[52]
Tecfidera	DM2OVDT	Approved	Tecfidera increases the expression of Ferritin light chain (FTL).	[53]
Amiodarone	DMUTEX3	Phase 2/3 Trial	Amiodarone increases the expression of Ferritin light chain (FTL).	[54]
DNCB	DMDTVYC	Phase 2	DNCB increases the expression of Ferritin light chain (FTL).	[50]
PEITC	DMOMN31	Phase 2	PEITC increases the expression of Ferritin light chain (FTL).	[55]
APR-246	DMNFADH	Phase 2	APR-246 affects the expression of Ferritin light chain (FTL).	[56]
Disulfiram	DMCL2OK	Phase 2 Trial	Disulfiram increases the expression of Ferritin light chain (FTL).	[50]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene decreases the expression of Ferritin light chain (FTL).	[57]
Eugenol	DM7US1H	Patented	Eugenol increases the expression of Ferritin light chain (FTL).	[50]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A increases the expression of Ferritin light chain (FTL).	[58]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A increases the expression of Ferritin light chain (FTL).	[59]
Milchsaure	DM462BT	Investigative	Milchsaure increases the expression of Ferritin light chain (FTL).	[50]
Sulforaphane	DMQY3L0	Investigative	Sulforaphane increases the expression of Ferritin light chain (FTL).	[60]
chloropicrin	DMSGBQA	Investigative	chloropicrin increases the expression of Ferritin light chain (FTL).	[61]
Deguelin	DMXT7WG	Investigative	Deguelin increases the expression of Ferritin light chain (FTL).	[62]
methyl p-hydroxybenzoate	DMO58UW	Investigative	methyl p-hydroxybenzoate increases the expression of Ferritin light chain (FTL).	[63]
cinnamaldehyde	DMZDUXG	Investigative	cinnamaldehyde increases the expression of Ferritin light chain (FTL).	[61]
acrolein	DMAMCSR	Investigative	acrolein increases the expression of Ferritin light chain (FTL).	[61]
Lead acetate	DML0GZ2	Investigative	Lead acetate increases the expression of Ferritin light chain (FTL).	[64]
1,6-hexamethylene diisocyanate	DMLB3RT	Investigative	1,6-hexamethylene diisocyanate increases the expression of Ferritin light chain (FTL).	[61]
NSC-1771	DMNXDGQ	Investigative	NSC-1771 increases the expression of Ferritin light chain (FTL).	[61]
Beta-D-Glucose	DM5IHYP	Investigative	Beta-D-Glucose increases the expression of Ferritin light chain (FTL).	[65]
CHLORANIL	DMCHGF1	Investigative	CHLORANIL increases the expression of Ferritin light chain (FTL).	[66]
methyl salicylate	DMKCG8H	Investigative	methyl salicylate increases the expression of Ferritin light chain (FTL).	[50]
2-Propanol, Isopropanol	DML5O0H	Investigative	2-Propanol, Isopropanol increases the expression of Ferritin light chain (FTL).	[50]
Citraconic acid	DMCIM9A	Investigative	Citraconic acid increases the expression of Ferritin light chain (FTL).	[53]

1 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Arsenic	DMTL2Y1	Approved	Arsenic affects the methylation of Ferritin light chain (FTL).	[40]

References

• [1] A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica. 2009 Mar;94(3):335-9. doi: 10.3324/haematol.2008.000125. Epub 2009 Jan 27.
• [2] Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.Eur J Haematol. 2019 Feb;102(2):131-142. doi: 10.1111/ejh.13183. Epub 2018 Nov 28.
• [3] Association of ferritin with prostate cancer.J BUON. 2017 May-Jun;22(3):766-770.
• [4] Decreased expression of ferritin light chain in osteosarcoma and its correlation with epithelial-mesenchymal transition.Eur Rev Med Pharmacol Sci. 2018 May;22(9):2580-2587. doi: 10.26355/eurrev_201805_14951.
• [5] A novel double nucleotide variant in the ferritin-L iron-responsive element in a Finnish patient with hereditary hyperferritinaemia-cataract syndrome.Acta Ophthalmol. 2018 Feb;96(1):95-99. doi: 10.1111/aos.13492. Epub 2017 Jun 21.
• [6] Neurodegeneration with brain iron accumulation.Handb Clin Neurol. 2011;100:161-72. doi: 10.1016/B978-0-444-52014-2.00009-4.
• [7] Ferritin Light Chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer.Carcinogenesis. 2020 Jun 17;41(4):467-477. doi: 10.1093/carcin/bgz181.
• [8] The relationship between depression and serum ferritin level.Eur J Clin Nutr. 2007 Apr;61(4):532-5. doi: 10.1038/sj.ejcn.1602542. Epub 2006 Oct 25.
• [9] Adult-onset generalized dystonia due to a mutation in the neuroferritinopathy gene.Mov Disord. 2005 Feb;20(2):243-5. doi: 10.1002/mds.20280.
• [10] Differential expression of insulin-like growth factor binding protein 1 and ferritin light polypeptide in gestational trophoblastic neoplasia: combined cDNA suppression subtractive hybridization and microarray study.Cancer. 2005 Dec 1;104(11):2409-16. doi: 10.1002/cncr.21483.
• [11] Raised serum ferritin concentration in hereditary hyperferritinemia cataract syndrome is not a marker for iron overload.Hepatology. 2014 Mar;59(3):1204-6. doi: 10.1002/hep.26681. Epub 2014 Jan 27.
• [12] Ferritin light chain and squamous cell carcinoma antigen 1 are coreceptors for cellular attachment and entry of hepatitis B virus.Int J Nanomedicine. 2012;7:827-34. doi: 10.2147/IJN.S27803. Epub 2012 Feb 16.
• [13] Genomewide investigation of the clinical implications and molecular mechanism of long noncoding RNA LINC00668 and proteincoding genes in hepatocellular carcinoma.Int J Oncol. 2019 Oct;55(4):860-878. doi: 10.3892/ijo.2019.4858. Epub 2019 Aug 14.
• [14] Ferritin light chain down-modulation generates depigmentation in human metastatic melanoma cells by influencing tyrosinase maturation.J Cell Physiol. 2006 Mar;206(3):843-8. doi: 10.1002/jcp.20543.
• [15] Discovery and analysis of inflammatory disease-related genes using cDNA microarrays.Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2150-5. doi: 10.1073/pnas.94.6.2150.
• [16] Characterization of the l-ferritin variant 460InsA responsible of a hereditary ferritinopathy disorder.Neurobiol Dis. 2006 Sep;23(3):644-52. doi: 10.1016/j.nbd.2006.05.004. Epub 2006 Jul 5.
• [17] Comparative proteomic analysis between normal skin and keloid scar.Br J Dermatol. 2010 Jun;162(6):1302-15. doi: 10.1111/j.1365-2133.2010.09660.x. Epub 2010 Feb 1.
• [18] The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
• [19] Aspirin increases ferroportin 1 expression by inhibiting hepcidin via the JAK/STAT3 pathway in interleukin 6-treated PC-12 cells.Neurosci Lett. 2018 Jan 1;662:1-5. doi: 10.1016/j.neulet.2017.10.001. Epub 2017 Oct 4.
• [20] Neuroferritinopathy.Int Rev Neurobiol. 2013;110:91-123. doi: 10.1016/B978-0-12-410502-7.00006-5.
• [21] Review: Insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories.Neuropathol Appl Neurobiol. 2016 Apr;42(3):220-41. doi: 10.1111/nan.12242. Epub 2015 Jun 2.
• [22] The role of the FTO (Fat Mass and Obesity Related) locus in regulating body size and composition.Mol Cell Endocrinol. 2014 Nov;397(1-2):34-41. doi: 10.1016/j.mce.2014.09.012. Epub 2014 Sep 16.
• [23] Screening, identification of prostate cancer urinary biomarkers and verification of important spots.Invest New Drugs. 2019 Oct;37(5):935-947. doi: 10.1007/s10637-018-0709-3. Epub 2019 Jan 4.
• [24] Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology. 2005 Aug 23;65(4):603-5. doi: 10.1212/01.wnl.0000178224.81169.c2.
• [25] Variation in iron homeostasis genes between patients with ARDS and healthy control subjects.Chest. 2008 Jun;133(6):1302-1311. doi: 10.1378/chest.07-1117. Epub 2007 Nov 7.
• [26] Expression of Ferritin Light Chain (FTL) Is Elevated in Glioblastoma, and FTL Silencing Inhibits Glioblastoma Cell Proliferation via the GADD45/JNK Pathway.PLoS One. 2016 Feb 12;11(2):e0149361. doi: 10.1371/journal.pone.0149361. eCollection 2016.
• [27] Ferritin: A potential serum marker for lymph node metastasis in head and neck squamous cell carcinoma.Oncol Lett. 2019 Jan;17(1):314-322. doi: 10.3892/ol.2018.9642. Epub 2018 Oct 30.
• [28] Elevated levels of ferritin in the cerebrospinal fluid of amyotrophic lateral sclerosis patients.Acta Neurol Scand. 2017 Aug;136(2):145-150. doi: 10.1111/ane.12708. Epub 2016 Nov 1.
• [29] Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.Int J Oncol. 2013 Nov;43(5):1481-6. doi: 10.3892/ijo.2013.2063. Epub 2013 Aug 20.
• [30] The role of transferrin receptor in the Helicobacter pylori pathogenesis; L-ferritin as a novel marker for intestinal metaplasia.Microb Pathog. 2019 Jan;126:157-164. doi: 10.1016/j.micpath.2018.10.039. Epub 2018 Oct 31.
• [31] Next-generation sequencing of hereditary hemochromatosis-related genes: Novel likely pathogenic variants found in the Portuguese population.Blood Cells Mol Dis. 2016 Oct;61:10-5. doi: 10.1016/j.bcmd.2016.07.004. Epub 2016 Jul 22.
• [32] Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance.Mol Cell Proteomics. 2009 Jan;8(1):172-89. doi: 10.1074/mcp.M800292-MCP200. Epub 2008 Sep 9.
• [33] Plasma hepcidin is associated with future risk of venous thromboembolism.Blood Adv. 2018 Jun 12;2(11):1191-1197. doi: 10.1182/bloodadvances.2018018465.
• [34] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [35] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [36] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [37] Lysosome Fe(2+) release is responsible for etoposide- and cisplatin-induced stemness of small cell lung cancer cells. Environ Toxicol. 2021 Aug;36(8):1654-1663. doi: 10.1002/tox.23161. Epub 2021 May 10.
• [38] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [39] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [40] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [41] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [42] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [43] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [44] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [45] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [46] High folic acid increases cell turnover and lowers differentiation and iron content in human HT29 colon cancer cells. Br J Nutr. 2008 Apr;99(4):703-8.
• [47] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [48] Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
• [49] Comparison of replicative senescence and stress-induced premature senescence combining differential display and low-density DNA arrays. FEBS Lett. 2005 Jul 4;579(17):3651-9. doi: 10.1016/j.febslet.2005.05.056.
• [50] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
• [51] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [52] Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med. 2008 Sep 15;45(6):763-72.
• [53] Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes. Mol Cell Biol. 2017 May 16;37(11):e00079-17. doi: 10.1128/MCB.00079-17. Print 2017 Jun 1.
• [54] Capturing time-dependent activation of genes and stress-response pathways using transcriptomics in iPSC-derived renal proximal tubule cells. Cell Biol Toxicol. 2023 Aug;39(4):1773-1793. doi: 10.1007/s10565-022-09783-5. Epub 2022 Dec 31.
• [55] Phenethyl isothiocyanate alters the gene expression and the levels of protein associated with cell cycle regulation in human glioblastoma GBM 8401 cells. Environ Toxicol. 2017 Jan;32(1):176-187.
• [56] Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 2010 Mar 4;29(9):1329-38. doi: 10.1038/onc.2009.425. Epub 2009 Nov 30.
• [57] Label-free quantitative proteomic analysis identifies the oncogenic role of FOXA1 in BaP-transformed 16HBE cells. Toxicol Appl Pharmacol. 2020 Sep 15;403:115160. doi: 10.1016/j.taap.2020.115160. Epub 2020 Jul 25.
• [58] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [59] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [60] Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. Food Chem Toxicol. 2020 Feb;136:111047. doi: 10.1016/j.fct.2019.111047. Epub 2019 Dec 12.
• [61] Gene expressions changes in bronchial epithelial cells: markers for respiratory sensitizers and exploration of the NRF2 pathway. Toxicol In Vitro. 2014 Mar;28(2):209-17.
• [62] Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615. doi: 10.1007/s00204-020-02970-5. Epub 2021 Jan 29.
• [63] Transcriptome dynamics of alternative splicing events revealed early phase of apoptosis induced by methylparaben in H1299 human lung carcinoma cells. Arch Toxicol. 2020 Jan;94(1):127-140. doi: 10.1007/s00204-019-02629-w. Epub 2019 Nov 20.
• [64] In vitro effects of lead on gene expression in neural stem cells and associations between up-regulated genes and cognitive scores in children. Environ Health Perspect. 2017 Apr;125(4):721-729.
• [65] Effects of Anaplasma phagocytophilum on host cell ferritin mRNA and protein levels. Infect Immun. 2005 Nov;73(11):7629-36. doi: 10.1128/IAI.73.11.7629-7636.2005.
• [66] Redox-active quinones induces genome-wide DNA methylation changes by an iron-mediated and Tet-dependent mechanism. Nucleic Acids Res. 2014 Feb;42(3):1593-605. doi: 10.1093/nar/gkt1090. Epub 2013 Nov 8.
• [67] cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat. 2006 Mar;96(1):17-39. doi: 10.1007/s10549-005-9026-6. Epub 2005 Dec 2.